Melchardt, T.
28  results:
Search for persons X
?
 
?
5

Correction: The influence of FCGR2A and FCGR3A polymorphism..:

Magnes, T. ; Melchardt, T. ; Hufnagl, C....
The Pharmacogenomics Journal.  20 (2019)  2 - p. 350-350 , 2019
 
?
6

UNMAINTAINED REMISSION AFTER DISCONTINUATION OF KINASE INHI..:

Egle, A. ; Jäger, U. ; Skrabs, C....
Hematological Oncology.  37 (2019)  S2 - p. 218-219 , 2019
 
?
7

The influence of FCGR2A and FCGR3A polymorphisms on the sur..:

Magnes, T ; Melchardt, T ; Hufnagl, C...
The Pharmacogenomics Journal.  18 (2017)  3 - p. 474-479 , 2017
 
?
8

Multiple myeloma of the mandibular condyle: a rare presenta..:

Bottini, G.B. ; Steiner, C. ; Melchardt, T..
British Journal of Oral and Maxillofacial Surgery.  55 (2017)  10 - p. 1046-1047 , 2017
 
?
10

Prognostic significance of Ki67 proliferation index, HIF1 a..:

Berghoff, A. S. ; Ilhan-Mutlu, A. ; Wöhrer, A....
Strahlentherapie und Onkologie.  190 (2014)  7 - p. 676-685 , 2014
 
?
11

R-CHOP versus R-COMP: Are They Really Equally Effective?:

Mian, M. ; Wasle, I. ; Gamerith, G....
Clinical Oncology.  26 (2014)  10 - p. 648-652 , 2014
 
?
12

Thrombozytopenie bei Autoimmunhämolyse: Verbrauch oder Myel..:

Melchardt, T. ; Weiss, L. ; Egle, A.
DMW - Deutsche Medizinische Wochenschrift.  138 (2013)  41 - p. 2093-2095 , 2013
 
?
13

5.28 Combining Fludarabine and Rituximab With Escalating Do..:

Egle, A. ; Steurer, M. ; Gassner, F....
Clinical Lymphoma Myeloma and Leukemia.  11 (2011)  - p. S261-S262 , 2011
 
?
15

Novel agents in diffuse large B-cell lymphoma: A short upda..:

Melchardt, T. ; Hofbauer, S. W. ; Greil, R..
memo - Magazine of European Medical Oncology.  4 (2011)  2 - p. 120-123 , 2011
 
1-15